CASI Pharmaceuticals 2025 Q3 Earnings Widened Net Loss of $10.88M Amid Revenue Drop

Generated by AI AgentAinvest Earnings Report DigestReviewed byAInvest News Editorial Team
Saturday, Nov 15, 2025 10:08 am ET1min read
CASI
--
Aime RobotAime Summary

-

CASI Pharmaceuticals
reported a 60.5% revenue drop to $3.08M and a 29.6% wider net loss of $10.88M in Q3 2025, missing expectations.

- Stock prices fell 31.52% month-to-date, with a 3-year buy-and-hold

strategy
yielding -71.17% cumulative returns, underperforming benchmarks.

- CEO David Cory highlighted $5.7M ATM financing, China business divestiture by Q2 2026, and CID-103 clinical progress in AMR/ITP trials to address financial strain.

- The company is appealing Nasdaq delisting risks while advancing CID-103 FDA clearance and presenting Phase 1 ITP trial results at ASH 2025.

CASI Pharmaceuticals reported its 2025 Q3 earnings on Nov 14, 2025, revealing a 60.5% year-over-year revenue decline and a 29.6% wider net loss. The results missed expectations, with no guidance adjustments provided.

Revenue

CASI’s total revenue plummeted to $3.08 million in Q3 2025, a 60.5% drop from $7.79 million in Q3 2024. The decline was driven by estimated returns of its cancer drug EVOMELA® under a modified distribution agreement with CRPCGIT.

Earnings/Net Income

The company’s losses deepened to $0.67 per share, a 21.8% increase in the per-share loss, with net losses widening to $10.88 million from $8.39 million. The EPS and net loss reflect deteriorating profitability, underscoring ongoing financial challenges.

Price Action

CASI’s stock price fell 5.43% in the latest trading day, 8.70% in the past week, and 31.52% month-to-date. A post-earnings buy-and-hold strategy since 2022 yielded a 3-year cumulative return of -71.17% (-25.38% annualized), far underperforming passive benchmarks.

CEO Commentary

CASI’s CEO, David Cory, emphasized advancing CID-103 in renal allograft AMR and ITP trials, while addressing Nasdaq delisting risks. “We remain focused on capitalizing on CID-103’s clinical progress in the U.S. and China,” Cory stated, noting the Phase 1 ITP results to be presented at ASH 2025. The CEO acknowledged financial strain but highlighted $5.7 million raised via ATM and a planned China divestiture by Q2 2026 as critical steps to stabilize operations.

Additional News

CASI is appealing its Nasdaq delisting determination, seeking an extension to meet market value requirements. The company also announced a $5.7 million raise via its ATM facility in Q3 2025 to fund operations. Separately, it plans to divest its China business by mid-2026, a move aimed at refocusing on core U.S. and global development programs. Clinical progress includes FDA clearance for CID-103 in renal allograft AMR and an ongoing Phase 1 ITP trial, with results to be presented at ASH 2025 on Dec 7.

Comments



Add a public comment...
No comments

No comments yet